2 May 2022
  • Share

In his regular PharmaTimes feature, sustainability columnist Joe Newcombe looks out to pharma’s cleaner, greener horizon.

Pharma is highly experienced in tackling complex problems for the benefit of society. Already possessing the necessary culture of innovation, technical expertise and financial resources, the sector is well placed to become a global leader in sustainability.

Nevertheless, the industry currently remains highly carbon intensive. A 2021 report from My Green Lab and Urgentem found that global emissions of the biotech and pharma industry equates to around 50% of the carbon output of the UK.

It found that while big pharma is making solid progress towards a zero-carbon future, if the lens is broadened, the top 65 companies instead show an opposite trend. Net increases in emissions are partly attributable to industry growth but that growth seems to be a shade of off-green.


Read the full column in PharmaTimes.

See Joe's other PharmaTimes columns.


As featured in



Joseph is a patent attorney working in the chemistry and materials field assisting in the drafting and prosecution of UK and European patents. He also has experience in opposition and appeal proceedings before the EPO and the management of national/regional phase entry of international patent applications.

Sign up to our newsletter: Forward - news, insights and features

Our People

Our IP specialists work at all stage of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.


Contact Us

We have an easily-accessible office in central London, as well as a number of regional offices throughout the UK and an office in Munich, Germany.  We’d love to hear from you, so please get in touch.